Polymathy: the knowledge of many arts and sciences. Specialising in one field is impressive enough - but to span as many as Dr Ted Achacoso is extraordinary. This week, Josh is joined in the studio by one of the greatest game-changers currently working in the biohacking sphere. From medicine to artificial intelligence and technology to investing, Dr Achacoso has seen it all. Listen on to hear about his incredible journey, his current work, and how he formulated the increasingly popular Blue Cannatine nootropic troche.
Curious about his full background? Read on for his story:
Dr. Ted Achacoso earned his college degree in Biology at the age of 18 and his Doctor of Medicine degree at the age of 22. At 25, he was a fellow of interventional neuroradiology, a research professor of pharmacology and toxicology, and a clinical professor of neurology in Manila. At 28, he became a professor of medical informatics and of interventional neuroradiology in Washington, DC, where he also performed artificial intelligence research biased towards connectionist systems. At 30, he began science and technology consulting for socially responsible investment funds. At 35, he founded and ran a group collaboration software company and created the first wireless groupware. At 40 he traded currencies using artificial intelligence predictive techniques for a private fund. At 45, he retrained in Interventional Endocrinology (Anti-Aging Medicine) and in Nutritional Medicine in Paris, and became double board-certified in both specialties. Dr. Ted wrote the first-ever connectome (of C. elegans) in a book, is published in peer-reviewed scientific journals, holds US patents and software algorithms, provides TV and podcast interviews, and delivers lectures. He currently has a tri-continental practice in Health Optimization Medicine (HOMe), a clinical framework that he pioneered to include health management in a disease management practice. He also formulated the Blue Cannatine nootropic troche, a product in the Troscriptions line of Smarter Not Harder, Inc.